SOLVENT-DETERGENT TREATMENT OF IgM-ENRICHED IMMUNOGLOBULIN
|
|
- Lee Newton
- 5 years ago
- Views:
Transcription
1 DARU Volume 11, No. 2, 2003 SOLVENT-DETERGENT TREATMENT OF IgM-ENRICHED IMMUNOGLOBULIN * MOJGAN POURMOKHTAR, ** RASSOUL DINARVAND, * KAMRAN MOUSAVI HOSSEINI, * HOURI REZVAN, * MOHAMMAD ALI JALILI * R&D Department, Iranian Blood Research and Fractionation Co., Tehran, Iran ** Department. of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. ABSTRACT Viral safety of human plasma products plays a key role in their safe uses. Solvent- detergent (SD) virus-inactivation method has gained widespread popularity in the manufacture of biological products. This treatment which inactivates lipid-enveloped viruses effectively consists of incubation of a plasma protein solution in the presence of a non-volatile organic solvent and a detergent. In this study, IgMenriched immunoglobulin was incubated at 24 C for 6 h under slow stirring in the presence of tri(nbutyl) phosphate (0.3% w/w ) as solvent and tween 80 (1% w/w) as detergent. After completion of the inactivation process and removal of the solvent-detergent, the ability of SD-treatment to remove Infectious Bovine Rhinotracheitis (IBR) virus (a lipid-enveloped virus) and Foot-and-Mouth Disease virus (a non-enveloped virus) were evaluated by "virus spiking studies" using a scaled down process. Reduction factor of 4 log was obtained for the SD-treatment of IgM-enriched immunoglobulin spiked with IBR virus. No virus inactivation was observed in the SD-treated IgM-enriched immunoglobulin, spiked with Foot-and-Mouth Disease virus. It was concluded that treatment of IgM-enriched immunoglobulin with TNBP-TWEEN 80 may be considered as an efficient lipid-enveloped virus inactivation step in the manufacture of this product. Key words: Solvent-detergent, Virus inactivation, IgM, Tween 80, Bovine rhinotracheitis virus INTRODUCTION Plasma derivatives which comprise an increasing variety of therapeutic products such as polyvalent immunoglobulins are obtained by pooling plasma of donors. Hence a manufacturing approach that comprises specific measures to ensure very high margin of viral safety is required (1). In other words, viral safety of plasma products plays a key role in their safe uses (2). Fractionation of plasma by ethanol precipitation (3) and protein purification by chromatography (4), at least in part, contribute to the partitioning of viruses and are important tools in optimizing plasma product viral safety(5). However, manufacturers no longer depend on Cohn- Oncley cold ethanol fractionation as the only viral elimination step (6). They have implemented rigorous donor screening plasma testing, good manufacturing practices and additional viral inactivation and validation steps (7) in the manufacturing processes in order to provide viral safety of the plasma products (1,5,8). The most commonly used viral inactivation or elimination treatments are solvent-detergent incubation (9), pasteurization (10), nanofiltration (11), specific dry heat and steam heat treatments, acid ph incubation, combination of beta propiolactone and UV irradiation (8) and photochemical inactivation (1). Since the introduction of modern viral inactivation treatments by solvent-detergent or pasteurization in industry, risks of transmission of the highly pathogenic plasma-borne lipidenveloped viruses (HIV, HBV and HCV) by plasma products have essentially been eliminated (12). The solvent-detergent virus inactivation method has gained widespread popularity in the manufacture of biological products. This popularity arises from several advantages of the treatment such as: its high virucidal action, high protein compatibility, ease of insertion into virtually any pre-existing or newly developed purification process, and the availability of extensive documentation (13). Solvent-detergent treatment consists of incubation of a plasma protein solution in the presence of a non-volatile organic solvent such as tri-(nbutyl) phosphate (TNBP) at a concentration of 0.3% (w/w) and a detergent such as tween 80 at Correspondace: Rassoul Dinarvand, Department. of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran 14174, Iran, dinarvan@sina.tums.ac.ir
2 Pourmokhtar et al a concentration of 1% (w/w) (10). This treatment which leads to an efficient viral inactivation by disruption of the structural integrity of lipid-enveloped viruses (14) without alteration in recovery or physiological functions or increase in immunogenicity of plasma proteins (14-16), is generally performed at temperatures between 24 C and 30 C over a maximum of 6 hours under mild stirring (13,17). SD treatment of plasma or immunoglobulin solution followed by virucidal reagents removal by oil extraction and column chromatography, has a proven safety record for Factor VIII products (13) and intravenous immunoglobulins (16). However in most cases SD method is combined with pasteurization at 60 C which ensures inactivation of a wide range of the SDresistant viruses without lipid envelopes (18). Dichtelmuller et al used beta-propiolactone treatme nt for inactivation of viruses in IgMenriched immunoglobulin (8). In this study Solvent-detergent treatment and pasteurization were used for inactivation of enveloped and non-enveloped viruses in IgM-enriched immunoglobulin. The primary target in the fractionation process of each plasma derivatives is inactivation of highly pathogenic plasmaborne lipid-enveloped viruses. An appropriate level of safety against these viruses can be achieved by introduction of techniques involving the use of solvent-detergent treatment and pasteurization (18). MATERIALS AND METHODS IgM-enriched immunoglobulin was produced by cold ethanol fractionation followed by octanoic acid treatment (8). Schematic representation of the manufacturing processes is shown in Fig.1. Reagents: Tri-(n-butyl)phosphate, tween 80, n-hexan, perchloric acid and heptanoic acid were obtained from Merck. Ricinus oil was obtained from Pharm. Raffiniert. Sephadex DEAE A-50 was obtained from Pharmacia Biotech. Viruses: Infectious Bovine Rhinotracheitis (IBR) virus, a member of Herpesviridae family, as a lipidenveloped DNA virus and Foot-and-Mouth Disease Virus (a member of Aphthovirus generation and Picornaviridae family), as a nonenveloped RNA virus, were used for validation of the extent of virus removal during processing. Solvent-detergent treatment The mixture of IgM-enriched immunoglobulin, Human Plasma Cold ethanol fractionation Fraction III Octanoic acid treatment Alcohol precipitation Reconstitution Solvent-detergent treatment Ricinus oil extraction DEAE Sephadex adsorption Virus inactivated IgM-enriched immunoglobulin Fig. 1. Schematic representation of the manufacturing processes for solvent-detergent treated IgMenriched immunoglobulin. tri-(n-butyl)phosphate (0.3% w/w ) and tween 80 (1% w/w) was kept at room temperature (24±2 C) for 6 hours under slow stirring. After completion of the inactivation process, Ricinus oil (5% v/v) was added graduatly under moderate stirring during 45 min. Then the stirring was stopped and the mixture was allowed to stand for 30 min in order to assure a complete separation of the oil and plasma layers and removal of tri-(n-butyl) phosphate. The plasma layer was withdrawn and cleared using 0.45 ìm filter (15). Thereafter, the clear IgMenriched immunoglobulin was passed over a sephadex DEAE A-50 column for the removal of tween 80. Validation of virus inactivation The ability of solvent-detergent treatment to remove relevant viruses was evaluated by virus spiking studies using a scaled down process. IBR virus and Foot-and-Mouth Disease Virus of high titer were added to the IgM-enriched immunoglobulin separately and the manufacturing process was carried out on a laboratory scale. Then ten-fold serial dilutions of samples were made in culture medium and the infectivity titres of cythopatic effects (CPE) inducing viruses were calculated according to Spearman Kaerber (8), which provides the preferred detection system for infectivity determination and virus quantification (8,19).
3 Solvent-detergent treatment of immunoglobulin Virus titre A B Time (min) Fig. 2. Time dependent inactivation of IBR virus by solvent-detergent treatment in IgM-enriched immunoglobulin, A: mixture of IgM-enriched immunoglobulin, TNBP(solvent) and Tween 80 (detergent) spiked with IBR virus, B: IgM-enriched immunoglobulin spiked with IBR virus without solvent-detergent as control RESULTS AND DISCUSSION Table 1 shows results of the process validation studies. In this table, reduction factors (RI) expressed in logarithmic scale which were determined by subtracting the log of the total virus found at the end of the process from which was present initially (9,19), and calculated according to the following equation (20): 10 RI = (V 10 á )/ (V 10 a ) In which, V = Volume of starting material, 10 á = virus titre in starting material, V = Volume of final material, and 10 a = virus titre in final material. The level of virus reduction which is considered acceptable for a single step is 4 log (19). Achievement of a reduction factor of 4 for IBR virus by solvent-detergent treatment of IgMenriched immunoglobulin, proved that the method which was used in this study may be considered as an efficient virus inactivation step in manufactur ing of this product. TNBP-Tween 80 treatment of IgM-enriched immunoglobulin inactivates lipid-enveloped viruses but allows retention of the biologic activity of the proteins highly (15,16). Time-dependent inactivation of IBR virus by tri-(n-butyl) phosphate (0.3% w/w )-tween 80 (1% w/w) treatment is shown in fig.2. The expression of reduction factors (RI) as logarithmic reductions in titre imply that residual virus infectivity may be greatly reduced, but it will never be reduced to zero (20). Table 1. Inactivation of IBR virus in IgM-enriched immunoglobulin by solvent-detergent treatment (TNBP-Tween 80) Treatment Virus Reduction Duration (min) Titre* Factor * These values are means of three tes ts in each step Although ethanol contributes to elimination of viruses both by partitioning and a direct virucidal effect (14), it does not appear to be sufficient to ensure the virus safety of IgMenriched immunoglobulin. However, by incorporation of the additional viral security methods such as solvent-detergent treatment, pasteurization and octanoic acid treatment, this product would appear to be safe and efficacious.
4 Pourmokhtar et al The use of almost any virus, animal or otherwise, can provide useful information in "virus spiking studies". Animal viruses can be selected because of the relevant virus properties (19), e.g. presence or absence of an envelope, size and physico-chemical properties. In this study the process validation studies utilizing spiking experiments with IBR virus and Footand-Mouth Disease virus were performed to give a quantitative estimate virus inactivation s degree by Solvent-detergent treatment of IgMenriched immunoglobulin. IgM-enriched immunoglobulin, spiked with Foot-and-Mouth Disease virus, was treated with tri-(n-butyl)phosphate (0.3% w/w )-tween 80 (1% w/w) and as it was expected, no virus inactivation was observed. Viral validation studies have demonstrated that the processes differ in their capabilities to inactivate lipid and non lipid-enveloped viruses (6). Besides, the International Association of Biological Standardization (IABS) recommends that at least two independent steps for virus inactivation are to be carried out. Therefore, the solvent-detergent method which leads to efficient inactivation of lipid-enveloped viruses need to be combined with pasteurization to ensure inactivation of a wide range of SDresistant viruses without lipid-envelopes (18). REFERENCES 1. Burnouf, T., Radosevich, M. (2000) Reducing the risk of infection from plasma products: Specific preventative strategies. Blood Reviews 14: Josic, D., Schulz, P., Biesert, L., Hoffer, L., Schwinn, H., Kordis-Krapez, M., Strancar, A. (1997) Issues in the development of medical products based on human plasma. J. Chromatogr. B. 649: Roussel, R.H., McCue, J.P. (1991) Antibody purification from plasma. In: Blood seperation and plasma fractionation. Harris, J.R., ed. New york: Wiley-liss, pp: Burnouf, T. (1995) Chromatography in plasma fractionation: benefits and future trends. J. Chromatogr. B. 664: Hellstern, P. (1994) Clinical experience with the viral safety of immunoglobulins. Blood Coagul. Fibrinolysis 5(3): S31-S Ballow, M. (2002) Intravenous immunoglobulins: Clinical experience and viral safety. J. Am. Pharm. Assoc. 42: Committee for proprietary medicinal products (CPMP): AD HOC Working Party on Biotechnology. (1998) Note for guidence on plasma-derived medicinal products. EMEA: Dichtelmuller, h., Rudnick, D., Breuer, B., Ganshirt K.H. (1993) Validation of virus inactivation and removal for the manufacturing procedure of two immunoglobulins and a 5% serum protein solution treated with B-propiolactone. Biologicals 21: Rutler, G.H. (1994) Requirements for safety and quality of intravenous immunoglobulin G preparations. J. Neurol. Neurosurg. Psychiatry 57(suppl): Chandra, S., Cavanaugh, J.E., Lin, C.M.,Piere-Jerome, c., Yerram, N., Weeks, R., Flanigan, E., and Feldman, F. (1999) Virus reduction in the preparation of intravenous immune globuline: in vitro experiments. Transfusion 39: Burnouf-Radosevich, M., Appourchaux, P., Huart, J.J., Burnouf, T. (1994) Nanofiltration, a new specific virus elimination method applied to high-purity Factor IX and Factor XI cocentrares. Vox. Sang. 67: Tabor, E. (1999) The epidemiology of virus transmission by plasma derivatives: Clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion 39: Horowitz, B., Prince, A.M., Hamman, J., Watklevicz, C. (1994) Viral safety of solvent / detergent-treated blood products. Blood Coag. Fibrinolysis 5(3): S21- S Eriksson, B., Westman, L., Jernberg, M. (1994) Virus validation of plasma-derived products produced by Pharmacia, with particular referance to immunoglobulins. Blood Coag. Fibrinolysis 5(3): S37-S Hellstern, P., Sachse, H., Schwinn, H., Oberfrank, K. (1992) Manufacture and in vitro characterization of a solvent/detergent-treated human plasma. Vox. Sang. 63:
5 Solvent-detergent treatment of immunoglobulin 16. Chidwick, K., Matejtschuk, P., Gascoigne, E., Briggs, N., More, J., Dash, C. (1999) Clinical experience with a new solvent detergent-treated intravenous immunoglobulin free of hypotensive effects. Vox. Sang. 77: Mould, G.P., Sutton, J.A., Matejtschuk, P., Gascoigne, E.W., Dash, C.H. (2001) Solvent / detergent treatment does not alter the tolerance or uptake of human Normal Immunoglobulin for injection. Vox. Sang. 80: Viral elimination or inactivation methods. (1999) In: Plasma fractio nation programmes for developing countries: Technical aspects and infrastructural requirements. WHO Regional Publications, Eastern Mediterranean series. pp: Roberts, P. (1996) Virus safety of plasma products. Medical Virology 6: Committee for proprietary medicinal products: AD HOC working party on biotechnology/pharmacy and working party on safety of medicines. (1991) Note for guidance on validation of virus removal and inactivation procedures. Biologicals 19:
Preparation of factor VII concentrate using CNBr-activated Sepharose 4B immunoaffinity chromatography
Original Article Medical Journal of the Islamic Republic of Iran (MJIRI) Iran University of Medical Sciences Preparation of factor VII concentrate using CNBr-activated Sepharose 4B immunoaffinity chromatography
More informationSolvent-Detergent for Virus Inactivation: An Evolving Technology Peter Roberts Bio Products Laboratory Elstree, UK
Solvent-Detergent for Virus Inactivation: An Evolving Technology Peter Roberts Bio Products Laboratory Elstree, UK Sixth Plasma Product Biotechnology Meeting Menorca, 11-25 May 2009 Summary Background
More informationObjectives. Methods. Results. Economic
Octaplas Compared with Fresh Frozen Plasma to Reduce the Risk of Transmitting Lipid-Enveloped Viruses: An Economic Analysis and Budget Impact Analysis [Adapted from Membe SK, Coyle D, Husereau D, Cimon
More informationViral clearance (inactivation and. Part 3a, Plasma and Plasma Products (Heat and Solvent/Detergent Treatments)
Part 3a, Plasma and Plasma Products (Heat and Solvent/Detergent Treatments) This article was first published in BioPharm s September 2002 issue. Gail Sofer Viral clearance (inactivation and removal) is
More informationPathogen Safety and BSE / variant CJD
Pathogen Safety and BSE / variant CJD Thomas R. Kreil, Global Pathogen Safety Parenteral Drug Industry Plasma Protein Industry Summit September 7, 2017; Beijing Pathogen Safety Those who cannot remember
More informationMagdy El Ekiaby, MD Shabrawishi Hospital BTC & HTC Cairo, Egypt
Magdy El Ekiaby, MD Shabrawishi Hospital BTC & HTC Cairo, Egypt Are plasma and cryoprecipitate still used? They are still largely used for treatment of hereditary bleeding disorders in many resource limited
More informationDraft Agreed by Biologics Working Party December Draft Agreed by Blood Products Working party December 2010
15 December 2011 EMA/CHMP/BWP/360642/2010 rev. 1 Committee for Medicinal Products for Human Use (CHMP) Guideline on the warning on transmissible agents in summary of product characteristics (SmPCs) and
More informationA comparison of the removal of parvovirus B19 and model parvoviruses from plasma products by virus filtration
A comparison of the removal of parvovirus B19 and model parvoviruses from plasma products by virus filtration Shirley Stagg, Samantha Fernando, Amy Shackell, Peter Roberts, Joan Dalton Bio Products Laboratory,
More informationHEMOFIL M Antihemophilic Factor (Human) Method M, Monoclonal Purified
HEMOFIL M Antihemophilic Factor (Human) Method M, Monoclonal Purified Description HEMOFIL M, Antihemophilic Factor (Human) (AHF), Method M, Monoclonal Purified, is a sterile, nonpyrogenic, dried preparation
More informationGuidelines on Viral Inactivation and Removal Procedures Intended to Assure the Viral Safety of Human Blood Plasma Products
WORLD HEALTH ORGANIZATION ORGANIZATION MONDIALE DE LA SANTE ENGLISH ONLY EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 26 to 30 November 2001 Guidelines on Viral Inactivation and Removal Procedures
More informationEnsuring Compliance: Regulatory guidance for virus clearance validation
Application Note Ensuring Compliance: Regulatory guidance for virus clearance validation Introduction To assure virus safety of biological therapeutics, regulatory guidance advocates an approach in which
More informationImmune Globulin Comparison Table
I. Formulation data Gamunex /IGIVnex Gammagard Liquid Privigen Vivaglobin Formulation Lyophilized Liquid Liquid Liquid Liquid Concentration 5% or 10% upon reconstitution Administration set provided? IgA
More informationOriginal Articles SAFETY OF BLOOD AND PLASMA DERIVATIVES: PATHOGEN REDUCING TECHNOLOGIES
Medical Journal of the Volume 20 Islamic Republic of Iran Number 2 Summer 1385 July 2006 Original Articles SAFETY OF BLOOD AND PLASMA DERIVATIVES: PATHOGEN REDUCING TECHNOLOGIES H. REZVAN, Z. MOTALLEBI,
More informationHepa%%s E Virus Is it a Concern?
IPFA/PEI 17 th Workshop on Surveillance and Screening of Blood Borne Pathogens 26-27 May 2010, The Regent Esplanade Zagreb Hotel, Zagreb, Croa%a Hepa%%s E Virus Is it a Concern? Keiji Matsubayashi Hokkaido
More informationHyper-Immune Globulin
Cytomegalovirus Cytogam Intramuscular GamaSTAN S/D Hepatitis B HepaGAM B HyperHEP B S/D Nabi - HB Rabies HyperRAB S/D IMOGAM Rabies - HT Tetanus HyperTET S/D (D) HyperRho S/D RhoGAM UF PLUS Rhophylac WinRho
More informationProduct Monograph. Key Scientific Information
Product Monograph Key Scientific Information Ko ate -DVI (Double Viral Inactivation) Infusion of more than 2 billion IUs worldwide with no confirmed cases of viral transmission.* Talecris is a leader in
More informationPlasma for fractionation: South African Plasma Requirements
Plasma for fractionation: South African Plasma Requirements Dr Jeh-han Omarjee Head: Microbiological Sciences NBI is a "not for profit" company committed to providing safe, cost effective, quality medicinal
More informationNew Advances in Transfusion EM I LY CO BERLY, M D
New Advances in Transfusion EM I LY CO BERLY, M D TRANSFUSI ON M EDI CI NE FELLO W VANDERBI LT UNI VERSITY Objectives To discuss the terminology, components, transfusion risks, and dosing guidelines for
More informationZpracování lidské plazmy
Zpracování lidské plazmy a bezpečnost koncentrátů plazmových pa pote proteinů ů MUDr. Ivan Vonke, OKH, Nemocnice Č.Budějovice, a.s. Raw material blood Hormons Proteins More than 120 plasma proteins 70-80g/Liter
More informationPREPARATION OF HIGHLY PURIFIED SOLVENT DETERGENT COA GULATION FACTOR VII AND FACTOR IX CONCENTRATES FROM PROTHROMBIN COMPLEX (PPSB)
Medical Journal of the Islamic Republic ofiran Volume 15. Number 2 Summer 1380 August 2001 PREPARATION OF HIGHLY PURIFIED SOLVENT DETERGENT COA GULATION FACTOR VII AND FACTOR IX CONCENTRATES FROM PROTHROMBIN
More informationGuidance for Industry
Guidance for Industry Use of Nucleic Acid Tests on Pooled and Individual Samples from Donors of Whole Blood and Blood Components (including Source Plasma and Source Leukocytes) to Adequately and Appropriately
More informationHEMOFIL M Antihemophilic Factor (Human), Method M, Monoclonal Purified Nanofiltered
HEMOFIL M Antihemophilic Factor (Human), Method M, Monoclonal Purified Nanofiltered DESCRIPTION HEMOFIL M, Antihemophilic Factor (Human) (AHF), Method M, Monoclonal Purified, is a sterile, nonpyrogenic,
More informationEMEA WORKSHOP ON VIRAL SAFETY OF PLASMA-DERIVED MEDICINAL PRODUCTS WITH PARTICULAR FOCUS ON NON-ENVELOPED VIRUSES. 13 September 2000 REPORT SUMMARY
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 28 March 2001 CPMP/BWP/BPWG/4080/00 EMEA WORKSHOP ON VIRAL SAFETY OF PLASMA-DERIVED MEDICINAL
More informationMeta Analysis of Virus Partitioning in Fractionation
Meta Analysis of Virus Partitioning in Fractionation Dr. Herbert Dichtelmüller Director Virus Validation Biotest; Dreieich, Germany IPFA/PEI Meeting; Budapest; May 2012 0 Cold Ethanol Fractionation Developed
More informationEXTRACTION OF LIPIDS FROM HUMAN BLOOD PLASMA USING COMPRESSED GASES
EXTRACTION OF LIPIDS FROM HUMAN BLOOD PLASMA USING COMPRESSED GASES Andreas Bezold*, Gerd Brunner Technical University Hamburg-Harburg Department of Thermal Process Engineering 21071 Hamburg, Germany bezold@tu-harburg.de,
More informationBlood transfusion. Dr. J. Potgieter Dept. of Haematology NHLS - TAD
Blood transfusion Dr. J. Potgieter Dept. of Haematology NHLS - TAD General Blood is collected from volunteer donors >90% is separated into individual components and plasma Donors should be: healthy, have
More informationPlasma Fractionation Issues for Developing Countries DR YASMIN AYOB
Plasma Fractionation Issues for Developing Countries DR YASMIN AYOB Plasma Fractionation Evolved from a medical service to a global manufacturing industry Involves sophisticated industrial process High
More informationPlasma Protein Therapeutics Association
Plasma Protein Therapeutics Association Mary Gustafson Vice President, Global Regulatory Policy, PPTA MASAC Update, September 20, 2014 Emerging Viruses and Product Safety Issues to be Addressed Presentation
More informationHuman Hepatitis B Immunoglobulin, solution for intramuscular injection.
New Zealand Data Sheet Hepatitis B Immunoglobulin-VF NAME OF THE MEDICINE Human Hepatitis B Immunoglobulin, solution for intramuscular injection. DESCRIPTION Hepatitis B Immunoglobulin-VF is a sterile,
More informationPHARMACOPOEIA MONOGRAPH
MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION Human coagulation factor IX PHARMACOPOEIA MONOGRAPH PM.3.3.2.0004.15 First Edition The present Pharmacopoeia Monograph applies to human coagulation factor IX
More informationCSL Behring LLC Albuminar -25 US Package Insert Albumin (Human) USP, 25% Revised: 01/2008 Page 1
Page 1 CSL Behring Albuminar -25 Albumin (Human) USP, 25% R x only DESCRIPTION Albuminar -25, Albumin (Human) 25%, is a sterile aqueous solution of albumin obtained from large pools of adult human venous
More informationdonors and collecting blood and plasma in for-profit or a not for profit environment
Remunerated versus non-remunerated donors and collecting blood and plasma in for-profit or a not for profit environment ISBT Amsterdam, June 4, 2013 Jan M. Bult President PPTA PATIENT CENTEREDNESS IT
More informationSource Plasma Safety
Source Plasma Safety Plasma May 15-19, 2017 George Schreiber, ScD, PPTA Director, Epidemiology Three components: Plasma Product Safety Donor Quality Manufacturing Pool Quality Fractionation Process Safe
More informationEpidemiology of Hepatitis C Iran
Seyed Moayed Alavian M.D. Professor of Gastro & Hepatology Editor-in-chief of Glob Hepat Comm Editor-in-chief of Hepatitis Monthly E mail: editor@hepatmon.com Epidemiology of Hepatitis C Iran Epidemiology
More informationExperience with Standardisation of Blood Virology NAT. Clare Morris Division of Retrovirology National Institute for Biological Standards and Control
Experience with Standardisation of Blood Virology NAT Clare Morris Division of Retrovirology National Institute for Biological Standards and Control Background of Blood Virology Standardisation In the
More informationIn previous articles of this viral inactivation. Part 6, Inactivation Methods Grouped by Virus
Part 6, Inactivation Methods Grouped by Virus This article was first published in BioPharm International s April 2003 issue. Gail Sofer, Dorothy C. Lister, and Jeri Ann Boose In previous articles of this
More informationDuration: 12 months May to April
SPECIALIST CERTIFICATE IN TRANSFUSION SCIENCE PRACTICE PROGRAMME OF STUDY OVERVIEW Example only Duration: 12 months May to April This document serves as a general programme overview only. To ensure you
More informationWHO Parvovirus B19 Genotype Panel
WHO Parvovirus B19 Genotype Panel Mei-ying W Yu, PhD SoGAT XXII Rome, 14-15 April 2011 1 st WHO International Reference Panel for Parvovirus B19 Genotypes In Oct 2009, a plasma-derived parvovirus B19 (B19V)
More informationFor Research Use Only Ver
INSTRUCTION MANUAL Quick-DNA/RNA Pathogen Miniprep Catalog Nos. R1042 & R1043 Highlights Spin-column purification of pathogen (virus, bacteria, protozoa) DNA/RNA from a wide variety of vectors (mosquitoes,
More informationIVD information *Droppers for the sensitized and control cells. Not for use other than dispensing the sensitized and control cells.
In Vitro Diagnostic Reagent Instruction Manual of Diagnostic Reagent for Determination of anti-hbs Thoroughly read this instruction manual before use of this kit Background of the development and features
More informationFor purification of viral DNA and RNA from a wide range of sample materials
QIAamp virus kits For purification of viral DNA and RNA from a wide range of sample materials Automatable on QIAGEN s proven QIAamp Kits set the standard for purification of viral DNA and RNA. QIAamp virus
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) CORE SPC FOR HUMAN NORMAL IMMUNOGLOBULIN FOR SUBCUTANEOUS AND INTRAMUSCULAR USE (CPMP/BPWG/282/00)
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit London, 25 July 2002 EMEA/ COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) CORE SPC FOR HUMAN NORMAL IMMUNOGLOBULIN
More informationHuman Zoster Immunoglobulin, solution for intramuscular injection.
Product Information Zoster Immunoglobulin-VF Australia NAME OF THE MEDICINE Human Zoster Immunoglobulin, solution for intramuscular injection. DESCRIPTION Zoster Immunoglobulin-VF is a sterile, preservative-free
More informationViral vaccines. Lec. 3 أ.د.فائزة عبد هللا مخلص
Lec. 3 أ.د.فائزة عبد هللا مخلص Viral vaccines 0bjectives 1-Define active immunity. 2-Describe the methods used for the preparation of attenuated live & killed virus vaccines. 3- Comparison of Characteristics
More informationImmunologic Products asdhealthcare.com
Immunologic Products Bivigam Carimune NF Flebogamma DIF Gammagard S/D Low IGA Gammagard Liquid Gammaked Gammaplex Gamunex -C Hizentra HyQvia Octagam Privigen Immunologic Products 800.746.6273 asdhealthcare.com
More informationViruses challenge biopharmaceutical
Virus Inactivation in the 1990s and into the 21st Century Part 3b, Plasma and Plasma Products (Treatments Other than Heat or Solvent/Detergent) Gail Sofer The latest installment of our series on recently
More informationDRAFT PROPOSAL FOR THE INTERNATIONAL PHARMACOPOEIA: CARBAMAZEPINI COMPRESSI - CARBAMAZEPINE TABLETS
December 2015 Draft document for comment 1 2 3 4 5 6 DRAFT PROPOSAL FOR THE INTERNATIONAL PHARMACOPOEIA: CARBAMAZEPINI COMPRESSI - CARBAMAZEPINE TABLETS (December 2015) REVISED DRAFT FOR COMMENT Should
More informationLEVONORGESTREL AND ETHINYLESTRADIOL TABLETS. (January 2012) DRAFT FOR COMMENT
January 2012 RESTRICTED DRAFT PROPOSAL FOR The International Pharmacopoeia LEVONORGESTREL AND ETHINYLESTRADIOL TABLETS (January 2012) DRAFT FOR COMMENT This document was provided by a quality control expert.
More informationCYCLOSERINI CAPSULAE - CYCLOSERINE CAPSULES (AUGUST 2015)
August 2015 Document for comment 1 2 3 4 5 CYCLOSERINI CAPSULAE - CYCLOSERINE CAPSULES DRAFT PROPOSAL FOR THE INTERNATIONAL PHARMACOPOEIA (AUGUST 2015) DRAFT FOR COMMENT 6 Should you have any comments
More informationIMOGAM RABIES PASTEURIZED - HUMAN RABIES IMMUNOGLOBULIN. Active ingredient: Human proteins mg
IMOGAM RABIES PASTEURIZED - HUMAN RABIES IMMUNOGLOBULIN COMPOSITION 1 ml of human rabies immunoglobulin contains: Active ingredient: Human proteins 100 180 mg containing (IgG class) human rabies immunoglobulins
More informationFor Research Use Only Ver
INSTRUCTION MANUAL Quick-RNA Viral Kit Catalog Nos. R1034 & R1035 Highlights Quick, spin-column purification of viral RNA from plasma, serum, CSF, cell culture media, cellular suspensions, urine, blood,
More informationConfirmed (Laboratory Tests) Serum positive for IgM anti-hbc or, hepatitis B surface antigen (HbsAg).
Hepatitis B Hepatitis B is a liver disease that results from infection with the Hepatitis B virus. It can range in severity from a mild illness lasting a few weeks to a serious, lifelong illness. Hepatitis
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT. octaplaslg, solution for infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT octaplaslg, solution for infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION A 200 ml bag contains 9-14 g of ABO-blood group specific
More informationProduct Contents... 1 Specifications... 1 Product Description... 2 Buffer Preparation... 3 Protocol Appendix... 5 Ordering Information...
INSTRUCTION MANUAL Quick-DNA/RNA Pathogen MagBead Catalog Nos. R2145 & R2146 Highlights High-throughput, magnetic-bead based purification of pathogen (virus, bacteria, protozoa) DNA/RNA from a wide variety
More informationONE STEP (Lemon, Mint, Pine) Detergent for Cleaning, Disinfecting and Deodorizing
SUMMARY OF ANTIMICROBIAL ACTIVITY ONE STEP (Lemon, Mint, Pine) Detergent for Cleaning, Disinfecting and Deodorizing Description One Step is an effective economical 4 ounce per gallon disinfectant, specifically
More informationEMTRICITABINE AND TENOFOVIR TABLETS
September 2010 RESTRICTED EMTRICITABINE AND TENOFOVIR TABLETS Draft proposal for The International Pharmacopoeia (September2010) REVISED DRAFT FOR COMMENT This document was provided by a quality control
More informationVIRUS VALIDATION STUDIES: THE DESIGN, CONTRIBUTION AND INTERPRETATION OF STUDIES VALIDATING THE INACTIVATION AND REMOVAL OF VIRUSES
VIRUS VALIDATION STUDIES: THE DESIGN, CONTRIBUTION AND INTERPRETATION OF STUDIES VALIDATING THE INACTIVATION AND REMOVAL OF VIRUSES Guideline Title Virus Validation Studies: The Design, Contribution and
More informationThe Removal of Viruses During the Purification of Equine Antisera using Filtration Aids Hyflo Super-Cel Y and Fulmont Y Super A
Biologicals (2000) 28, 169 174 doi:10.1006/biol.2000.0254, available online at http://www.idealibrary.com on The Removal of Viruses During the Purification of Equine Antisera using Filtration Aids Hyflo
More informationProposed 1 st IS for Hepatitis E Virus RNA WHO/BS/
www.pei.de Proposed 1 st IS for Hepatitis E Virus RNA WHO/BS/09.2126 S. Baylis, Division of Virology, Paul-Ehrlich-Institut, Langen, Germany SoGAT XXII 14 th -15 th April 2011, Rome, Italy Presented at:
More informationRegulation of FMD vaccines within the European Union
Introduction Regulation of FMD vaccines within the European Union K De Clercq 1 and D K J Mackay 2 Appendix 36 The EUFMD European Pharmacopoeia Working Group made a proposal for revision of the FMD vaccine
More informationLaboratory Diagnosis of Viral Infections. G. Jamjoom 2005
Laboratory Diagnosis of Viral Infections G. Jamjoom 2005 Five Main Techniques: Virus Culture and Isolation Serology Rapid Detection of Viral Antigens Detection of Viral Nucleic Acid Electron Microscopy
More informationThe Microbiology and Virology Laboratory. Volume --- FINAL REPORT VIRUCIDAL EFFICACY TEST USING SWINE INFLUENZA A VIRUS (H1N1) Test Agent Anolyte
MICRO I TEST The Microbiology and Virology Laboratory Volume --- FINAL REPORT VIRUCIDAL EFFICACY TEST USING SWINE INFLUENZA A VIRUS (H1N1) Test Agent Anolyte Lot Numbers Oct 4, 2009 Sept 25, 2009 Data
More informationManual. Precision Red Advanced Protein Assay Reagent. Cat. # ADV02. cytoskeleton.com. Cytoskeleton, Inc.
The Protein Experts Manual Cytoskeleton, Inc. V. 6.0 Precision Red Advanced Protein Assay Reagent Cat. # ADV02 cytoskeleton.com Phone: (303) 322.2254 Fax: (303) 322.2257 Customer Service: cserve@cytoskeleton.com
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT, solution for infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION is presented as a ABO-blood group specific solution for infusion
More informationViral Hepatitis - Historical Perspective
Viral Hepatitis - Historical Perspective Infectious A E Enterically transmitted Viral hepatitis NANB Serum B D F, G,? other C Parenterally transmitted Before the discovery of hepatitis A virus (HAV) and
More informationRoche Molecular Biochemicals Application Note No. HP 1/1999
Roche Molecular Biochemicals Application Note No. HP 1/1999 Nucleic Acid Purification High Pure Viral Nucleic Acid Kit High Pure 16 System Viral Nucleic Acid Kit Efficiency of Hepatitis C Virus sample
More informationHuman Immunodeficiency Virus type 1 (HIV-1) gp120 / Glycoprotein 120 ELISA Pair Set
Human Immunodeficiency Virus type 1 (HIV-1) gp120 / Glycoprotein 120 ELISA Pair Set Catalog Number : SEK11233 To achieve the best assay results, this manual must be read carefully before using this product
More informationKeeping the Blood Supply Safe Current and Future Strategies. Marissa Li, MD
Keeping the Blood Supply Safe Current and Future Strategies Marissa Li, MD Overview Pre-collection Donor Screening Collection Visual Inspection Aseptic Processing Leukoreduction of Apheresis Collections
More informationFactor VIII Concentrate Factor IX Complex (Coagulation Factors, II, VII, IX, X) Concentrate. From: European Plasma Fractionation Association (EPFA)
Factor VIII Concentrate Factor IX Complex (Coagulation Factors, II, VII, IX, X) Concentrate Application for retention on the WHO Model List From: European Plasma Fractionation Association (EPFA) 1. Summary
More informationNucleic acid: singled stranded, double stranded, RNA, or DNA, linear or circular. Capsid: protein coat that is most of the mass of the virus.
Viruses General Characteristics of Viruses 1. Depending on view may be regarded as exceptionally complex aggregates of nonliving chemicals or as exceptionally simple living microbes. 2. Contain a single
More informationFor Research Use Only Ver
INSTRUCTION MANUAL Quick-DNA/RNA Viral MagBead Catalog Nos. R2140 & R2141 Highlights High-throughput, magnetic-bead based purification of viral DNA and RNA from plasma, serum, urine, cell culture media,
More informationDRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA PAEDIATRIC RETINOL ORAL SOLUTION (August 2010)
August 2010 RESTRICTED DRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA PAEDIATRIC RETINOL ORAL SOLUTION (August 2010) DRAFT FOR COMMENT This document was provided by a quality control expert and was
More informationWHO Blood Regulators Network (BRN)
Distribution: General English only WHO Blood Regulators Network (BRN) Position Paper on Collection and Use of Convalescent Plasma or Serum as an Element in Middle East Respiratory Syndrome Coronavirus
More informationDRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA EFAVIRENZ, EMTRICITABINE AND TENOFOVIR TABLETS
September 2010 RESTRICTED DRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA EFAVIRENZ, EMTRICITABINE AND TENOFOVIR TABLETS (August 2010) DRAFT FOR COMMENT This document was provided by a quality control
More informationMICROBIOLOGICAL PROFILE
Evans Vanodine International plc G L O B A L H Y G I E N E S O L U T I O N S HANDSAN MICROBIOLOGICAL PROFILE 2 INTRODUCTION HANDSAN is a ready to use, quick acting and highly effective, alcohol based hygienic
More informationUsing Donor Human Milk in Extremely Premature Infants
Using Donor Human Milk in Extremely Premature Infants Introduction Scott Eaker, Vice President of Quality and Regulatory Affairs Scott Elster, Chief Executive Officer David Rechtman, MD, Chief Medical
More informationHepatitis B Antiviral Drug Development Multi-Marker Screening Assay
Hepatitis B Antiviral Drug Development Multi-Marker Screening Assay Background ImQuest BioSciences has developed and qualified a single-plate method to expedite the screening of antiviral agents against
More informationPATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER
Verified with regard to factual content 13.12.2011 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER GAMMA anty-hbs 1000 Immunoglobulinum humanum hepatitidis B Human immunoglobulin against Hepatitis
More informationStudy N 286V AGRI GERM /14
Study N 286V15-2015-01 1/14 TEST REPORT VIRUCIDAL ACTIVITY OF THE PRODUCT AGAINST THE ENTERIC CYTOPATHOGENIC BOVINE ORPHAN VIRUS (ECBO) Delivered to: For : Mme FELBACQ-SERRANO Laboratoires CEETAL 1, rue
More informationBUMINATE 25% Albumin (Human), USP, 25% Solution
BUMINATE 25% Albumin (Human), USP, 25% Solution Description BUMINATE 25%, Albumin (Human), 25% Solution is a sterile, nonpyrogenic preparation of albumin in a single dosage form for intravenous administration.
More informationUvA-DARE (Digital Academic Repository) Viral safety of blood and plasma products Terpstra, F.G. Link to publication
UvA-DARE (Digital Academic Repository) Viral safety of blood and plasma products Terpstra, F.G. Link to publication Citation for published version (APA): Terpstra, F. G. (2007). Viral safety of blood and
More informationEVALUATION OF THE EFFECTIVENESS OF A 7% ACCELERATED HYDROGEN PEROXIDE-BASED FORMULATION AGAINST CANINE PARVOVIRUS
Final report submitted to Virox Technologies, Inc. EVALUATION OF THE EFFECTIVENESS OF A 7% ACCELERATED HYDROGEN PEROXIDE-BASED FORMULATION AGAINST CANINE PARVOVIRUS Syed A. Sattar, M.Sc., Dip. Bact., M.S.,
More informationDELFIA Tb-N1 DTA Chelate & Terbium Standard
AD0029P-1 (en) 1 DELFIA Tb-N1 DTA Chelate & AD0012 Terbium Standard For Research Use Only INTRODUCTION DELFIA Tb-N1 DTA Chelate is optimized for the terbium labeling of proteins and peptides for use in
More informationResponse to Modified Live and Killed Multivalent Viral Vaccine in Regularly Vaccinated, Fresh Dairy Cows*
E. J. Dubovi, Y. T. Gröhn, M. A. Brunner, and J. A. Hertl Response to Modified Live and Killed Multivalent Viral Vaccine in Regularly Vaccinated, Fresh Dairy Cows* Edward J. Dubovi, PhD a Yrjo T. Gröhn,
More informationPROPOSAL FOR REVISION OF MONOGRAPH PUBLISHED IN The International Pharmacopoeia: REVISION OF ph test ABACAVIR ORAL SOLUTION (JULY 2012)
July 2012 RESTRICTED PROPOSAL FOR REVISION OF MONOGRAPH PUBLISHED IN The International Pharmacopoeia: REVISION OF ph test ABACAVIR ORAL SOLUTION (JULY 2012) PROPOSED REVISION FOR COMMENT The background
More informationQSEAL Recovered Plasma Specification
QSEAL Recovered Plasma Specification Background The is part of a series of standards that comprise the Plasma Protein Therapeutics Association (PPTA) QSEAL Standards Program. PPTA's Voluntary Standards
More informationOverview of Blood Transfusion System of Iran:
Report Article Overview of Blood Transfusion System of Iran: 2002-2011 AM Cheraghali High Institute for Research and Education on Transfusion Medicine, Iran Blood Transfusion Organization and University
More informationRebaudioside a From Multiple Gene Donors Expressed in Yarrowia Lipolytica
Residue Monograph prepared by the meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), 82 nd meeting 2016 Rebaudioside a From Multiple Gene Donors Expressed in Yarrowia Lipolytica This
More informationCALIBRATION OF ANALYTICAL STANDARDS FOR HBV-DNA, HCV-RNA AND HIV-1 RNA IN GENOME COPIES BY A REFERENCE METHOD
CALIBRATION OF ANALYTICAL STANDARDS FOR HBV-DNA, HCV-RNA AND HIV-1 RNA IN GENOME COPIES BY A REFERENCE METHOD AAJ van Drimmelen, E.R. Bax and W.G.V. Quint, BioQControl (BQC), Delft Diagnostic Laboratories
More informationThe cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations Jackson B R, Busch M P, Stramer S L, AuBuchon J P
The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations Jackson B R, Busch M P, Stramer S L, AuBuchon J P Record Status This is a critical abstract of an economic evaluation that meets
More informationOriginal article J Bas Res Med Sci 2017; 4(2):4-8.
Prevalence of HIV, hepatitis B and C infections among volunteer blood donors at the blood transfusion center of Ilam city, Iran Hasan Boustani 1, Enayat Anvari 2, Sedighe Saiadi Sartang 2, Mehdi Omidi
More informationViral structure م.م رنا مشعل
Viral structure م.م رنا مشعل Viruses must reproduce (replicate) within cells, because they cannot generate energy or synthesize proteins. Because they can reproduce only within cells, viruses are obligate
More informationTo detect antibodies to Avian Influenza (AI) using the haemagglutination inhibition test in avian serum specimens 2.
SADC Harmonized SOP for Avian Influenza HA and HI Serological Tests Prepared by: Dr. P.V. Makaya, Dr. Joule Kangumba and Ms Delille Wessels Reviewed by Dr. P.V. Makaya 1. Purpose and scope To detect antibodies
More informationFresh Citrus Disinfectant Cleaner
SUMMARY OF ANTIMICROBIAL ACTIVITY Fresh Citrus Disinfectant Cleaner Description Fresh Citrus Disinfectant Cleaner is an effective economical 4 ounce per gallon disinfectant, specifically designed for hospitals,
More informationBe ready. The INTERCEPT Blood System for Platelets and Plasma pathogen reduction system
Be ready. The INTERCEPT Blood System for Platelets and Plasma pathogen reduction system INTERCEPT Blood System for Platelets an Blood safety is changing Safe donated blood is critical to improving certain
More informationKeeping blood transfusions safe:
ISP-WIV Seminar Diagnosis and surveillance of infectious diseases May 18 th, 2017 Keeping blood transfusions safe: the challenge of emerging infectious diseases Presented by Roland HÜBNER Superior Health
More informationOverview of comments received on 'Guideline on the clinical investigation of hepatitis B immunoglobulins' (EMA/CHMP/BPWP/585257/2009)
23 July 2015 EMA/CHMP/BPWP/356886/2013 Committee for Medicinal Products for Human Use (CHMP) Overview of comments received on 'Guideline on the clinical investigation of hepatitis B immunoglobulins' (EMA/CHMP/BPWP/585257/2009)
More informationpatients with blood borne viruses Controlled Document Number: Version Number: 4 Controlled Document Sponsor: Controlled Document Lead:
CONTROLLED DOCUMENT Procedure for the management of patients with blood borne viruses CATEGORY: CLASSIFICATION: PURPOSE Controlled Document Number: Version Number: 4 Controlled Document Sponsor: Controlled
More information